GDC-0973

GPTKB entity

Statements (34)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
investigational drug
gptkbp:approvedBy gptkb:European_Union
gptkb:United_States
gptkbp:ATCCode L01EE39
gptkbp:brand gptkb:Cotellic
gptkbp:CASNumber 934660-93-2
gptkbp:combines gptkb:vemurafenib
gptkbp:developedBy gptkb:Exelixis
gptkb:Genentech
gptkbp:hasMolecularFormula C21H20F3N5O2
gptkbp:hasSMILES CC(C)(O)N1CCN(CC1)C(=O)C2=CC(=C(C=C2F)NC3=CC(=C(C=C3)F)I)F
gptkbp:hasUNII Q1ZXA2J1XK
https://www.w3.org/2000/01/rdf-schema#label GDC-0973
gptkbp:IUPACName (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][4-(2-hydroxypropan-2-yl)piperazin-1-yl]methanone
gptkbp:KEGGID D10541
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction MEK inhibitor
gptkbp:PubChem_CID gptkb:CHEMBL1743088
25102825
28536941
DB09020
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
diarrhea
fatigue
rash
photosensitivity
gptkbp:synonym gptkb:cobimetinib
gptkbp:target gptkb:MEK1
gptkb:MEK2
gptkbp:usedFor melanoma
gptkbp:bfsParent gptkb:Cotellic
gptkbp:bfsLayer 7